Lifeward Announces Postponement of its Extraordinary General Meeting of Shareholders
28 December 2024 - 9:49AM
Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a
global market leader delivering life-changing solutions to
revolutionize what is possible in rehabilitation, recovery, and the
pursuit of life’s passions in the face of physical limitation or
disability, today announced that the Company’s Extraordinary
General Meeting of Shareholders (the “Meeting), which was
originally scheduled to be held on Monday, December 30, 2024, has
been postponed. The Meeting is now scheduled to be held at 10:00
a.m. (Eastern Standard Time) on Monday, January 13, 2025 at the
Company’s offices at 200 Donald Lynch Blvd., Marlborough, MA 01752,
U.S.A. The record date for the Meeting, November 20, 2024, is
unchanged and applies to the postponed Meeting.
The Meeting has been postponed due to an anticipated lack of
quorum, and to provide further time to solicit proxies from the
Company’s shareholders. Lifeward’s Board of Directors unanimously
recommends that you vote FOR the proposals identified in the
Company's proxy statement for the Meeting. Shareholders who have
already cast their votes do not need to take any action, unless
they wish to change or revoke their prior proxy or voting
instructions, and their votes will be counted at the postponed
Meeting. For shareholders who have not yet cast their votes, we
urge them to vote their shares now, so they can be tabulated prior
to the postponed Meeting.
The Company plans to hold an Investor Day soon after the
Meeting, with the exact date to be confirmed.
Important Additional Information
The Company has filed a Definitive Proxy Statement with the
Securities and Exchange Commission (the “SEC”) on November 25,
2024 (the “Proxy Statement”), which should be read in conjunction
with this notice. To the extent information in this notice updates
or conflicts with information contained in the Proxy Statement, the
information in this notice is the more current information.
SHAREHOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY
AMENDMENTS OR SUPPLEMENTS THERETO) FILED BY LIFEWARD AND ANY OTHER
RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR
ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION
ABOUT ANY SOLICITATION. Shareholders may obtain a free copy of the
proxy statement and the other relevant materials, and any other
documents filed by Lifeward with the SEC, at the SEC's web site
at https://www.sec.gov or on the "SEC Filings" section of
Lifeward’s website at https://golifeward.com/.
About Lifeward
Lifeward designs, develops, and commercializes life-changing
solutions that span the continuum of care in physical
rehabilitation and recovery, delivering proven functional and
health benefits in clinical settings as well as in the home and
community. Our mission at Lifeward is to relentlessly drive
innovation to change the lives of individuals with physical
limitations or disabilities. We are committed to delivering
groundbreaking solutions that empower individuals to do what they
love. The Lifeward portfolio features innovative products including
the ReWalk Exoskeleton, the AlterG Anti-Gravity System, the
MyoCycle FES System, and the ReStore Exo-Suit.
Founded in 2001, Lifeward has operations in the United
States, Israel, and Germany. For more information on the
Lifeward product portfolio, please visit GoLifeward.com.
Lifeward®, ReWalk®, ReStore® and Alter G® are
registered trademarks of Lifeward Ltd. and/or its
affiliates.
Forward-Looking Statements
In addition to historical information, this press release
contains forward-looking statements within the meaning of
the U.S. Private Securities Litigation Reform Act of
1995, Section 27A of the U.S. Securities Act of 1933, as
amended, and Section 21E of the U.S. Securities Exchange
Act of 1934, as amended. Such forward-looking statements may be
identified by words like "anticipate," "assume," "believe,"
"continue," "could," "estimate," "expect," "intend," "may," "plan,"
"potential," "predict," "project," "future," "will," "should,"
"would," "seek" and similar terms or phrases. Such statements are
subject to numerous important factors, risks and uncertainties that
may cause actual events or results to differ materially from the
Company’s current expectations. These and other risks are more
fully discussed in the Company’s periodic filings with
the SEC, including the risk factors described under the
heading "Risk Factors" in the Company’s annual report on Form 10-K
and 10-K/A for the year ended December 31, 2023 filed
with the SEC and other documents subsequently filed with
or furnished to the SEC. Any forward-looking statement made in
this press release speaks only as of the date hereof. Factors or
events that could cause the Company’s actual results to differ from
the statements contained herein may emerge from time to time, and
it is not possible for the Company to predict all of them. Except
as required by law, Lifeward undertakes no obligation to publicly
update any forward-looking statements, whether as a result of new
information, future developments or otherwise.
Lifeward Media Relations:Kathleen O’DonnellVP Marketing &
New Business DevelopmentLifewardE: media@golifeward.com
Lifeward Investor Contact:Mike LawlessChief Financial
OfficerLifewardE: ir@golifeward.com
Lifeward (NASDAQ:LFWD)
Historical Stock Chart
From Nov 2024 to Dec 2024
Lifeward (NASDAQ:LFWD)
Historical Stock Chart
From Dec 2023 to Dec 2024